|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Genotype/Subtype
|
D |
|
Relevant Drug
|
lamivudine (LAM);telbivudine (LDT);entecavir (ETV) |
|
Country
|
Iran |
Literature Information
|
PubMed PMID
|
26300928
|
|
Disease
|
HBV infection
|
|
Published Year
|
2015 |
|
Journal
|
Hepatitis monthly |
|
Title
|
YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. |
|
Author
|
Rahimi R,Hosseini SY,Fattahi MR,Sepehrimanesh M,Safarpour A,Malekhosseini SA,Nejabat M,Khodadad M,Ardebili M |
|
Evidence
|
Critical M204I mutation, as a proof for resistance to LAM, was detected among 46% of the subjects and natural entecavir resistance (S202I) was also distinguished in one subject.
|
|
|
HBV Mutation Detail Information